{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:35:53Z","timestamp":1783654553173,"version":"3.55.0"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The French health authority (ANSM) is responsible for monitoring medicinal and other drug dependencies. To support these activities, the ANSM manages a network of 13 drug dependence evaluation and information centres (Centres d'Evaluation et d'Information sur la Pharmacod\u00e9pendance \u2010 Addictovigilance \u2010 CEIP\u2010A) throughout France. In 2006, the Nantes CEIP\u2010A created a new tool called the EGAP (Echelle de GrAvit\u00e9 de la Pharmacod\u00e9pendance\u2010 drug dependence severity scale) based on DSM IV criteria. This tool allows the creation of a substance use profile that enables the drug dependence severity to be homogeneously quantified by assigning a score to each substance indicated in the reports from health professionals. This article describes the validation and psychometric properties of the drug dependence severity score obtained from the scale ( <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/Clinicaltrials.gov\">Clinicaltrials.gov<\/jats:ext-link> NCT01052675).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>The validity of the EGAP construct, the concurrent validity and the discriminative ability of the EGAP score, the consistency of answers to EGAP items, the internal consistency and inter rater reliability of the EGAP score were assessed using statistical methods that are generally used for psychometric tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The total EGAP score was a reliable and precise measure for evaluating drug dependence (Cronbach alpha = 0.84; ASI correlation = 0.70; global ICC = 0.92). In addition to its good psychometric properties, the EGAP is a simple and efficient tool that can be easily specified on the official ANSM notification form.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The good psychometric properties of the total EGAP score justify its use for evaluating the severity of drug dependence.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13044","type":"journal-article","created":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T14:20:31Z","timestamp":1466000431000},"page":"1030-1039","source":"Crossref","is-referenced-by-count":5,"title":["Multicentre study for validation of the French addictovigilance network reports assessment tool"],"prefix":"10.1111","volume":"82","author":[{"given":"Caroline","family":"Victorri\u2010Vigneau","sequence":"first","affiliation":[{"name":"Pharmacology Department Nantes University Hospital, Institute of Biology, H\u00f4tel Dieu  9, Quai Moncousu 44093 Nantes Cedex 01 France"},{"name":"EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Measures in Health, UFR Pharmaceutical Sciences  1 rue Gaston Veil BP 53508, 44035 Nantes cedex 1 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Benoit","family":"Hardouin","sequence":"additional","affiliation":[{"name":"EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Measures in Health, UFR Pharmaceutical Sciences  1 rue Gaston Veil BP 53508, 44035 Nantes cedex 1 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Rousselet","sequence":"additional","affiliation":[{"name":"Pharmacology Department Nantes University Hospital, Institute of Biology, H\u00f4tel Dieu  9, Quai Moncousu 44093 Nantes Cedex 01 France"},{"name":"EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Measures in Health, UFR Pharmaceutical Sciences  1 rue Gaston Veil BP 53508, 44035 Nantes cedex 1 France"},{"name":"Addictology Department Nantes University Hospital, B\u00e2timent Louis Philippe  H\u00f4pital St Jacques, 85 rue Saint\u2010Jacques 44093 Nantes Cedex 1 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Gerardin","sequence":"additional","affiliation":[{"name":"Pharmacology Department Nantes University Hospital, Institute of Biology, H\u00f4tel Dieu  9, Quai Moncousu 44093 Nantes Cedex 01 France"},{"name":"EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Measures in Health, UFR Pharmaceutical Sciences  1 rue Gaston Veil BP 53508, 44035 Nantes cedex 1 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryl\u00e8ne","family":"Guerlais","sequence":"additional","affiliation":[{"name":"Pharmacology Department Nantes University Hospital, Institute of Biology, H\u00f4tel Dieu  9, Quai Moncousu 44093 Nantes Cedex 01 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Guillou","sequence":"additional","affiliation":[{"name":"Addictology Department Nantes University Hospital, B\u00e2timent Louis Philippe  H\u00f4pital St Jacques, 85 rue Saint\u2010Jacques 44093 Nantes Cedex 1 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bronnec","sequence":"additional","affiliation":[{"name":"EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Measures in Health, UFR Pharmaceutical Sciences  1 rue Gaston Veil BP 53508, 44035 Nantes cedex 1 France"},{"name":"Addictology Department Nantes University Hospital, B\u00e2timent Louis Philippe  H\u00f4pital St Jacques, 85 rue Saint\u2010Jacques 44093 Nantes Cedex 1 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"S\u00e9bille","sequence":"additional","affiliation":[{"name":"EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Measures in Health, UFR Pharmaceutical Sciences  1 rue Gaston Veil BP 53508, 44035 Nantes cedex 1 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Jolliet","sequence":"additional","affiliation":[{"name":"Pharmacology Department Nantes University Hospital, Institute of Biology, H\u00f4tel Dieu  9, Quai Moncousu 44093 Nantes Cedex 01 France"},{"name":"EA 4275 Biostatistics, Pharmacoepidemiology and Subjective Measures in Health, UFR Pharmaceutical Sciences  1 rue Gaston Veil BP 53508, 44035 Nantes cedex 1 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the French Addictovigilance Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7,28]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"47","article-title":"Les consommations de m\u00e9dicaments psychotropes en France","volume":"427","author":"Beck F","year":"2014","journal-title":"La sant\u00e9 en action"},{"key":"e_1_2_8_3_1","volume-title":"M\u00e9dicaments psychotropes : consommations et pharmacod\u00e9pendances","author":"INSERM","year":"2012"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2009.00096.x"},{"key":"e_1_2_8_5_1","unstructured":"Department of Health (England) and the devolved administrations.Drug Misuse and Dependence: UK Guidelines on Clinical Management. London 2007."},{"key":"e_1_2_8_6_1","first-page":"8","article-title":"Les niveaux d'usage des drogues en France en 2014, exploitation des donn\u00e9es du Barom\u00e8tre sant\u00e9 2014","volume":"99","author":"Beck F","year":"2015","journal-title":"Tendances"},{"key":"e_1_2_8_7_1","unstructured":"OFDT.Synth\u00e8se th\u00e9matique: cannabis 2016. Available athttp:\/\/wwwofdtfr\/produits\u2010et\u2010addictions\/de\u2010z\/cannabis\/(last accessed 25 September 2015)."},{"key":"e_1_2_8_8_1","unstructured":"EMCDDA.France country overview. A summary of the national drug situation 2016. Available athttp:\/\/wwwemcddaeuropaeu\/countries\/france(last accessed 25 September 2015)."},{"key":"e_1_2_8_9_1","first-page":"37","article-title":"Emerging drugs of abuse: current perspectives on substitued cathinones","volume":"5","author":"Paillet\u2010Loilier M","year":"2014","journal-title":"Subst Abuse Rehabil"},{"key":"e_1_2_8_10_1","first-page":"15","article-title":"The French system of evaluation of dependence: establishment in a legal system","volume":"56","author":"Baumevieille M","year":"2001","journal-title":"Therapie"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie:2008014"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1681"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/11587640-000000000-00000"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283400cb2"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0099-x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050246"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730030-00007"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2011.00950.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie:2006089"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/10826081003777568"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2012016"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1076725"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2008062"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02861.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-958522"},{"key":"e_1_2_8_26_1","first-page":"359","article-title":"Descriptive studies of the use of the Addiction Severity Index in France","volume":"22","author":"Martin C","year":"1996","journal-title":"Encephale"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/10826084.2011.640732"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.01.021"},{"key":"e_1_2_8_29_1","unstructured":"ANSM Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9.Notification form 2014. Available athttp:\/\/ansmsantefr\/Declarer\u2010un\u2010effet\u2010indesirable\/Votre\u2010declaration\u2010concerne\u2010un\u2010autre\u2010produit\u2010de\u2010sante\/Votre\u2010declaration\u2010concerne\u2010un\u2010autre\u2010produit\u2010de\u2010sante\/Votre\u2010declaration\u2010concerne\u2010une\u2010substance\u2010ou\u2010plante\u2010ayant\u2010un\u2010effet\u2010psychoactif(last accessed 25 September 2015)."},{"key":"e_1_2_8_30_1","volume-title":"Diagnostic and statistical manual of mental disorders","author":"APA","year":"2013"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1371868"},{"key":"e_1_2_8_32_1","unstructured":"ANSM Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9.Compte\u2010rendu de la Commission Nationale des Stup\u00e9fiants et des Psychotropes du 21 avril 2011.2011."},{"key":"e_1_2_8_33_1","unstructured":"ANSM Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9.Comit\u00e9 Technique des CEIP du 17 novembre 2014 2014. Available athttp:\/\/ansmsantefr\/Mediatheque\/Publications\/Ordres\u2010du\u2010jour\u2010comptes\u2010rendus\u2010des\u2010groupes\u2010de\u2010travail\u2010comites\u2010commissions\u2010Comites\u2010techniques(last accessed 25 September 2015)."},{"key":"e_1_2_8_34_1","unstructured":"ANSM Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9.Commission nationale des stup\u00e9fiants et des psychotropes.Compte\u2010rendu du 21 novembre 2013 2016. Available athttp:\/\/ansmsantefr\/var\/ansm_site\/storage\/original\/application\/ab78fffb49da3bf1ef109c45afc4a72apdf(last accessed 25 September 2015)."},{"key":"e_1_2_8_35_1","unstructured":"ANSM Liste_projets_retenus_ANSM_AAP_2012_2. 2012: ANSM;2012."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13044","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13044","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:54:35Z","timestamp":1696301675000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/bcp.13044"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13044","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]}}}